MOTS-c: The Mitochondrial Peptide for Metabolic Research

Research use only. This content is for laboratory research; not for human or veterinary use, diagnosis, or treatment.

What is MOTS-c

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid peptide (sequence: MRWQEMGYIFYPRKLR) with a molecular weight of 2174.5 Da and molecular formula C₁₀₀H₁₅₂N₂₈O₂₂S. Unlike most bioactive peptides, MOTS-c is encoded by the mitochondrial genome, specifically by a region of the 12S ribosomal RNA ^[1].

It was first identified in 2015 by Pinchas Cohen's group at the University of Southern California as part of an emerging family of mitochondrial-derived peptides (MDPs). The CAS number for MOTS-c is 1627580-64-6. Its mitochondrial origin suggests a role in retrograde communication between mitochondria and the cell nucleus.

Documented Mechanism of Action

Preclinical evidence indicates that MOTS-c acts primarily through activation of the AMPK (AMP-activated protein kinase) pathway, a critical cellular energy sensor. In cell culture and murine model studies, MOTS-c has been localized to both the cytoplasm and nucleus, where it interacts with antioxidant response elements (ARE) and regulates gene expression related to metabolism ^[2].

The mitochondrial peptide appears to exert metabolic effects through two main pathways: (1) direct activation of AMPK in skeletal muscle, which promotes insulin-independent glucose uptake, and (2) modulation of nuclear gene expression involved in folate metabolism and purine nucleotide pathways ^[1]. This mitochondria-nucleus communication represents a regulatory axis that responds to metabolic and stress signals.

In dietary restriction models, circulating MOTS-c levels increase, suggesting an adaptive role under conditions of energy scarcity. However, specific membrane receptors and complete signaling cascades have not yet been fully characterized.

What the Research Studies Show

Peer-reviewed literature documents the following findings in experimental models:

• In C57BL/6 mice fed a high-fat diet, MOTS-c treatment prevented weight gain and improved glucose tolerance compared to controls, with effects mediated by AMPK activation in skeletal muscle ^[1].
• In vitro studies with C2C12 myotubes demonstrated that MOTS-c increased 2-deoxyglucose uptake in a dose-dependent manner, suggesting a direct effect on glucose transport ^[2].
• In aged mice (22-24 months), MOTS-c improved physical performance in endurance tests and partially reversed markers of age-associated metabolic decline ^[3].
• Analysis of mt-12S rRNA gene polymorphisms in human populations revealed associations between specific variants (such as K14Q) and longevity in Japanese cohorts, although causal mechanisms require validation ^[4].
• In fatty acid-induced insulin resistance models, MOTS-c partially restored insulin signaling and reduced inflammatory markers in primary mouse hepatocytes ^[2].

Limitations of Current Evidence

The majority of MOTS-c studies have been conducted in immortalized cell lines and murine models. Clinical trials in humans are scarce and have small sample sizes. A phase I study reported in 2021 evaluated safety in healthy volunteers (n=16), but no metabolic efficacy results have been published in clinical populations ^[4].

Oral bioavailability and pharmacokinetic half-life in humans have not been established. Studies in rodents primarily used intraperitoneal administration, and dose extrapolation between species has not been validated. Additionally, potential interactions with medications or specific pathological conditions have not been systematically characterized.

The cellular receptor specificity for MOTS-c remains unidentified. Although AMPK activation is documented, it is unclear whether this is a direct effect or secondary to changes in cellular energy status. Finally, the functional relevance of mitochondrial polymorphisms observed in genetic association studies requires experimental validation.

Considerations for Research Protocols

Re/Vida supplies MOTS-c (SKU: MOTS-C-10MG) with full traceability via Certificates of Analysis. Current lot MOTS-2026-A01 presents purity ≥99.4% determined by HPLC and mass spectrometry, with expiration through December 2026. Each vial contains 10 mg of lyophilized peptide.

Reconstitution should be performed with sterile bacteriostatic water or saline solution, following appropriate laboratory protocols. Reconstituted peptide should be stored at 2-8°C and used within the period indicated by the experimental protocol. Lyophilized material is preserved at -20°C.

Documentation and Traceability

Each lot of MOTS-c includes a Certificate of Analysis with complete specifications: HPLC purity (≥98%), mass spectrometry-confirmed identity (2174.5 ± 2.0 Da), amino acid analysis, Karl Fischer water content, and endotoxin testing (<1.0 EU/mg). Documents are available for audit and publication.

Re/Vida maintains chain of custody from synthesis through delivery, with controlled storage at -20°C and shipping with pharmaceutical-grade refrigerants. Complete lot documentation enables experimental reproducibility and citation in scientific publications.